I do believe we spike on the news of the hold being

New Post Public Reply Private Reply Replies (3) Message Board
Respert24
944
I do believe we spike on the news of the hold being released, I just don't know how high. It could catch enough shorts off guard that the scramble to exit positions jumps it over a buck. Or it doesn't get close to that and only bumps up toward .50.

From there though, it's anyone's guess. I think it's entirely possible to see some really significant increases if we get quick news after the hold about either a partnership with a legit big pharma company or an announcement that a BLA is back in business with a near term possibility of an approval.

As far as a big pharma partner, I'm talking about Gilead or Merck level companies. If they're throwing around possibilities of combining LL eventually with a Keytruda, for instance, that should be quite the catapult for our price. But if it's a partnership with an unknown group with 8 employees we'll see the mechanism fail before the catapult even starts to pull. If they announce that Craig's Biotech & Animal Husbandry LLC has offered a very generous percentage on future sales for US rights I think we'd see the price fall.

In regards to a BLA, I'm not on board with the theory that they're just going to approve us out of the blue within a few weeks under guidance that we complete a phase 4 to shore up any missing information post approval. I think it's more likely that we either complete whatever that trial is first, or that we are allowed to resubmit a BLA, which gives the FDA six months to review and eventually approve. Either result would be fantastic, I just don't think we're going to jump from incomplete BLA that independent auditors say would fail instantly, to shoring up the safety hold and magically getting approval. If it took them two years to answer six questions from the FDA I can't imagine they also were able to complete a new BLA in that timeframe for the patient population they've just recently started to hone in on with the help of the FDA.

So while I like the idea of that reddit poster's 26 days to $35, I think it would take a lot longer than that for all of his predictions to play out. And I don't necessarily agree with all of them anyway. I'm not sold on the idea that Cytodyn moved their manufacturing tech somewhere else. I think the wording of the entire FAQ and letter, and specifically that paragraph where it's mentioned, means they were speaking historically of a significant hurdle that was achieved along the path to where we are now. Not a recent transfer that leads some to think a new partner will be taking that over.

I also don't think that announcing a MASH trial and getting it approved is something that happens quickly. They can announce they've submitted a protocol, but then the FDA will take 60+ days or something to review it and rubber stamp it.

But overall I do think we'll get news of the hold release followed by at least two more important PRs. Funding via a partnership of some kind should be one, and news about why the FDA hosted an ADCOM-style meeting about LL and HIV should be another. And those two or three things should help get us back into a respectable price range measured in dollars versus cents.

Oh, and up almost 4% right out of the gates today?

Somebody...

Must...

Know...

Something...

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 52

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 182

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 149

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 202

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 111

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 163

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 64

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 0

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
BD&J's Workplace Recognition Meets Los Angeles Growth Test

Updated Category News Views 58

A workplace award is not a verdict from a jury, but it can still tell you where a law firm is putting its money and attention. BD&J Injury Lawyers landed on the Los Angeles Business Journal's 2026 list of most admired law firms to work for, announced November 18. For a personal-injury practice trying to deepen its footing in a brutally crowded Los Angeles market, that is...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading

Top 5 Most Recently Viewed Articles

Delta Air Lines and Taiwan Semiconductor: Earnings Insights

Updated Category News Views 120

Delta Air Lines: Anticipated Earnings Report As we look ahead to the earnings season, all eyes are on Delta Air Lines. Sales projections indicate a modest increase of 0.8%, yet analysts predict a significant downturn of 15.2% in earnings. Despite some downward adjustments from analysts, Delta boasts an impressive history of surprising on earnings. Delta operates multiple...

Continue Reading
Vera Bradley Sees Share Price Decline Amid Revenue Challenges

Updated Category News Views 153

Vera Bradley Experiences Revenue Challenges Amid Market Pressures Vera Bradley, Inc. (NASDAQ: VRA) has recently faced a noteworthy drop in its stock price, which sank by 12.65% in premarket trading. This decline followed the company's second-quarter earnings report that, although it surpassed expectations, revealed that revenue fell short of what analysts had predicted....

Continue Reading
Organon's Q4 Earnings Results: Key Highlights for Investors

Updated Category News Views 188

Understanding Organon's Q4 Earnings Results Organon (NYSE: OGN) has recently shared its earnings report, revealing critical insights that every investor should consider. The report reflects the company's financial health and performance trends over the last quarter, helping stakeholders make informed decisions. Earnings Overview In a notable announcement, Organon reported...

Continue Reading
Expanding Mental Health Services: Ana Deeter Joins Relief

Updated Category News Views 222

Expanding Mental Health Services at Relief Mental Health Relief Mental Health is excited to announce the addition of Ana Deeter, PA-C, to their team at the Northbrook clinic. Deeter, who is a board-certified physician assistant, will enhance the clinic's psychiatric services and offer SPRAVATO® (esketamine) treatment to adults seeking support. A New Specialist for...

Continue Reading
Discover BLUETTI's Cutting-Edge Energy Innovations at CES 2026

Updated Category News Views 245

Revolutionizing Energy Solutions with BLUETTI At this year's CES, BLUETTI, a leader in energy storage solutions, introduced an array of revolutionary products under the theme 'Innovate for All'. These innovations cater to the diverse demands of modern living, providing freedom and resilience for homes, vehicles, and the planet. Key Innovations from BLUETTI As BLUETTI...

Continue Reading